EUVIMEDEUVIMED entdecken
Crossref

Synthesis of Imidazo[1,2‐ a ]pyridine‐Isoquinoline Derivatives as Potent EGFR Inhibiting Anticancer Agents

Mahendar Reddy Gunuguntla, Manjunatha Hanumantharayappa, Shiva Kumar Koppula

ChemistrySelect · 26.02.2024 · 9 (8)

DOI: 10.1002/slct.202304780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 21.02.2024. Verfasst von Mahendar Reddy Gunuguntla und 2 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herein, we synthesized some new imidazo[1,2‐a]pyridine‐isoquinoline hybrids ( 8 a – 8 x ) and investigated their anticancer activity on two human breast cancer cell lines, namely MCF‐7 and MDA‐MB231. Generally, most of them displayed higher activity on both breast cell lines than the reference drug. Specifically, compounds (2,6‐difluorophenyl)(6‐methoxy‐1‐(2‐phenylimidazo[1,2‐a]pyridin‐3‐yl)‐3,4‐dihydroisoquinolin‐2(1 H )‐yl)methanone, (6‐methoxy‐1‐(2‐phenyl imidazo[1,2‐a]pyridin‐3‐yl)‐3,4‐dihydroisoquinolin‐2(1H)‐yl)(6‐methoxy pyridin‐3‐yl)methanone, (6‐methoxy‐1‐(2‐phenylimidazo[1,2‐a]pyridin‐3‐yl)‐3,4‐dihydroisoquinolin‐2(1H)‐yl)(pyrimidin‐5‐yl) methanone, 6‐methoxy‐1‐(2‐phenylimidazo[1,2‐a]pyridin‐3‐yl)‐2‐(phenylsulfonyl)‐1,2,3,4‐tetrahydro isoquinoline, 6‐methoxy‐1‐(2‐phenyl imidazo[1,2‐a]pyridin‐3‐yl)‐2‐tosyl‐1,2,3,4‐tetrahydroisoquinoline, and 6‐methoxy‐2‐((4‐methoxyphenyl)sulfonyl)‐1‐(2‐phenylimidazo[1,2‐a] pyridin‐3‐yl)‐1,2,3,4‐tetrahydroisoquinoline showed higher activity against tested cancer cell lines as compared to the erlotinib. The ability of potent compounds to inhibit the tyrosine kinase EGFR was then studied and found that compounds (6‐methoxy‐1‐(2‐phenylimidazo[1,2‐a]pyridin‐3‐yl)‐3,4‐dihydroisoquinolin‐2(1H)‐yl)(pyrimidin‐5‐yl) methanone, 6‐methoxy‐1‐(2‐phenylimidazo[1,2‐a]pyridin‐3‐yl)‐2‐tosyl‐1,2,3,4‐tetra hydroisoquinoline, and 6‐methoxy‐2‐((4‐methoxyphenyl) sulfonyl)‐1‐(2‐phenylimidazo[1,2‐a]pyridin‐3‐yl)‐1,2,3,4‐tetrahydro isoquinoline exhibited promising potency in comparison to the erlotinib. In silico investigations of the most effective compounds were also performed to find interactions with the EGFR receptor that robustly bind to the protein, and energy estimates were in good agreement with the corresponding IC 50 values.

Zitieren

APA

Gunuguntla, M. R., Hanumantharayappa, M., & Koppula, S. K. (2024). Synthesis of Imidazo[1,2‐ a ]pyridine‐Isoquinoline Derivatives as Potent EGFR Inhibiting Anticancer Agents. ChemistrySelect, 9(8). https://doi.org/10.1002/slct.202304780

Vancouver

Gunuguntla MR, Hanumantharayappa M, Koppula SK. Synthesis of Imidazo[1,2‐ a ]pyridine‐Isoquinoline Derivatives as Potent EGFR Inhibiting Anticancer Agents. ChemistrySelect. 2024;9(8). doi:10.1002/slct.202304780

BibTeX
@article{Gunuguntla2024,
  author = {Gunuguntla, Mahendar Reddy and Hanumantharayappa, Manjunatha and Koppula, Shiva Kumar},
  title = {Synthesis of Imidazo[1,2‐ a ]pyridine‐Isoquinoline Derivatives as Potent EGFR Inhibiting Anticancer Agents},
  journal = {ChemistrySelect},
  year = {2024},
  volume = {9},
  number = {8},
  doi = {10.1002/slct.202304780}
}
Kostenlos starten →